Pancreatic Cancer Research

ResearcherKarolinska University HospitalActive in the last 2 years

Elena B. Rangelova

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3844-7265; OpenAlex author ID A5091021109, A5123339623. Sources: ClinicalTrials.gov.

Their work

Papers
28 (first author 3, last author 1)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
139
Papers, trials and grants by year

2014: 2 papers · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 3 papers · 2020: none · 2021: 4 papers · 2022: 1 paper · 2023: 4 papers, 1 trial · 2024: 2 papers · 2025: 3 papers · 2026: 6 papers

Papers 28

  1. Upfront surgery vs. neoadjuvant therapy in pancreatic cancer with venous involvement: a multicenter retrospective analysis. Co-author DOI 10.1007/s00423-026-04291-0↗
  2. Impact of cytoreductive surgery with HIPEC in the treatment of pancreatic cancer with peritoneal carcinomatosis: A systematic review. Co-author DOI 10.1016/j.ejso.2026.111908↗
  3. Staging laparoscopy to detect occult metastases in localized pancreatic cancer: global survey among nine international societies. Co-author DOI 10.1016/j.hpb.2025.12.001↗
  4. Neurogenic diarrhoea after superior mesenteric artery divestment or resection for pancreatic adenocarcinoma following preoperative chemotherapy: international … Co-author DOI 10.1093/bjsopen/zrag057↗
  5. Benefit of adjuvant chemotherapy for resected pancreatic cancer following neoadjuvant FOLFIRINOX or Gemcitabine-Nab-paclitaxel: a multinational analysis. Co-author DOI 10.1093/jnci/djag235↗
  6. ASO Visual Abstract: Survival Benefit of Surgery Versus Oncology-Only Therapy in Artery-Involving Borderline Resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18479-z↗
  7. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  8. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Co-author DOI 10.1016/j.annonc.2024.12.015↗
  9. Survival Benefit of Surgery versus Oncology-Only Therapy in Artery-Involving Borderline Resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18212-w↗
  10. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
  11. Exhausted Tumor-infiltrating CD39+CD103+ CD8+ T Cells Unveil Potential for Increased Survival in Human Pancreatic Cancer. Co-author DOI 10.1158/2767-9764.crc-23-0405↗
  12. Pancreatic cancer. First author DOI 10.1016/j.ejso.2023.01.001↗
  13. Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study. Co-author DOI 10.1245/s10434-022-12387-2↗
  14. FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analy… Co-author DOI 10.1245/s10434-023-13353-2↗
  15. Consensus Statement on the Use of Near-Infrared Fluorescence Imaging during Pancreatic Cancer Surgery Based on a Delphi Study: Surgeons' Perspectives on Curren… Co-author DOI 10.3390/cancers15030652↗
  16. Immunotherapy in pancreatic cancer-an emerging role: a narrative review. Co-author DOI 10.21037/cco-21-174↗
  17. Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer: A Single Institution Experience. Co-author DOI 10.1097/sla.0000000000003301↗
  18. Resectable, borderline, and locally advanced pancreatic cancer-"the good, the bad, and the ugly" candidates for surgery? Last author DOI 10.21037/jgo-2020-slapc-04↗
  19. How to select the most appropriate adjuvant treatment after neoadjuvant treatment and resection for locally advanced pancreatic cancer? Co-author DOI 10.21037/jgo-21-474↗
  20. Locally advanced pancreatic cancer-a resectable disease? Co-author DOI 10.21037/jgo-21-542↗
  21. Pancreatectomy with arterial resection is superior to palliation in patients with borderline resectable or locally advanced pancreatic cancer. First author DOI 10.1016/j.hpb.2018.07.017↗
  22. Neoepitope targets of tumour-infiltrating lymphocytes from patients with pancreatic cancer. Co-author DOI 10.1038/s41416-018-0262-z↗
  23. Response to Comment on "Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer". Co-author DOI 10.1097/sla.0000000000003418↗
  24. Prediction of improved survival in patients with pancreatic cancer via IL-21 enhanced detection of mesothelin epitope-reactive T-cell responses. Co-author DOI 10.18632/oncotarget.25121↗
  25. Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer. Co-author DOI 10.1097/cji.0000000000000111↗
  26. Enhanced tumor-infiltrating lymphocytes (eTIL) for cellular therapy of patients with pancreatic cancer or glioblastoma Co-author DOI 10.1186/2051-1426-3-s2-p35↗
  27. A fast assay to gauge for TAA-reactive T cells in PBMCS from patients with pancreatic cancer Co-author DOI 10.1186/2051-1426-2-s3-p25↗
  28. Generation of tumor-infiltrating lymphocytes from pancreatic cancer lesions for cellular therapy First author DOI 10.1186/2051-1426-2-s3-p26↗

Trials 1

  1. Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC Principal investigator NCT06714604↗

Closest collaborators

The 25 strongest of 139 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marc G. Besselink · 4 shared papers, 2025–2026 · strength 0.79
  2. Marco Del Chiaro · 4 shared papers, 2019–2026 · strength 0.68
  3. Ernesto Sparrelid · 3 shared papers, 2024–2026 · strength 0.62
  4. Benedetto Ielpo · 3 shared papers, 2025–2026 · strength 0.60
  5. Poya Ghorbani · 3 shared papers, 2024–2026 · strength 0.59
  6. Marco Del Chiaro · 5 shared papers, 2016–2026 · strength 0.54
  7. Helen Kaipe · 2 shared papers, 2022–2024 · strength 0.54
  8. Giuseppe Malleo · 3 shared papers, 2023–2026 · strength 0.53
  9. Asif Halimi · 3 shared papers, 2019–2026 · strength 0.50
  10. Svein Olav Bratlie · 2 shared papers, 2021 · strength 0.45
  11. Gabriella Lionetto Lionetto · 2 shared papers, 2026 · strength 0.41
  12. Allegra Ripolli · 2 shared papers, 2025–2026 · strength 0.41
  13. Kongyuan Wei · 2 shared papers, 2025–2026 · strength 0.41
  14. Emanuele F. Kauffmann · 2 shared papers, 2025–2026 · strength 0.41
  15. Riccardo Casadei · 2 shared papers, 2025–2026 · strength 0.41
  16. Sergio Alfieri · 2 shared papers, 2025–2026 · strength 0.41
  17. V. Egorov · 2 shared papers, 2025–2026 · strength 0.41
  18. Gregory G. Tsiotos · 2 shared papers, 2025–2026 · strength 0.41
  19. Alessandro Zerbi · 2 shared papers, 2025–2026 · strength 0.41
  20. Yuichi Nagakawa · 2 shared papers, 2025–2026 · strength 0.41
  21. Niccolò Napoli · 2 shared papers, 2025–2026 · strength 0.41
  22. Emilio Vicente · 2 shared papers, 2025–2026 · strength 0.41
  23. Ugo Boggi · 2 shared papers, 2025–2026 · strength 0.41
  24. Giuseppe Fusai · 2 shared papers, 2025–2026 · strength 0.41
  25. Roberto Coppola · 2 shared papers, 2025–2026 · strength 0.41

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.